Journal
VETERINARY QUARTERLY
Volume 43, Issue 1, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/01652176.2023.2240380
Keywords
Dog; canine PD-L1; anti-canine PD-L1 antibody; immune checkpoint inhibitor; >
Categories
Ask authors/readers for more resources
Immune escape, characterized by the overexpression of immune checkpoint ligands like PD-1/PD-L1, is a crucial mechanism in carcinogenesis. In this study, mouse anti-canine PD-L1 antibodies were developed for potential cancer immunotherapy in dogs. The antibodies effectively bound to canine cancer tissues and further investigations are needed to confirm their therapeutic potential and prognostic value.
Immune escape is the hallmark of carcinogenesis. This widely known mechanism is the overexpression of immune checkpoint ligands, such as programmed cell death protein 1 and programmed death-ligand 1 (PD-1/PD-L1), leading to T cell anergy. Therefore, cancer immunotherapy with specific binding to these receptors has been developed to treat human cancers. Due to the lack of cross-reactivity of these antibodies in dogs, a specific canine PD-1/PD-L1 antibody is required. The aim of this study is to develop mouse anti-canine PD-L1 (cPD-L1) monoclonal antibodies and characterize their in vitro properties. Six mice were immunized with recombinant cPD-L1 with a fusion of human Fc tag. The hybridoma clones that successfully generated anti-cPD-L1 antibodies and had neutralizing activity were selected for monoclonal antibody production. Antibody properties were tested by immunosorbent assay, surface plasmon resonance, and immunohistochemistry. Four hybridomas were effectively bound and blocked to recombinant cPD-L1 and cPD-1-His-protein, respectively. Candidate mouse monoclonal antibodies worked efficiently on formalin-fixed paraffin-embedded tissues of canine cancers, including cutaneous T-cell lymphomas, mammary carcinomas, soft tissue sarcomas, squamous cell carcinomas, and malignant melanomas. However, functional assays of these anti-cPD-L1 antibodies need further investigation to prove their abilities as therapeutic drugs in dogs as well as their applications as prognostic markers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available